Insider · CIK 0001588438

Shacham Sharon

Reports to the SEC for 3 companies · WATERTOWN, MA

sec.gov

Transactions

Companies

Filings

CIK

0001588438

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-17	ACRVAcrivon Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+20.3K sh	—	—	20,275
2026-05-18	ACRVAcrivon Therapeutics, Inc.A Award	Director	AAward	+9,366 sh	—	—	9,366
2025-06-13	ACRVAcrivon Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+20.3K sh	—	—	20,275
2024-06-20	ACRVAcrivon Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+20.3K sh	—	—	20,275
2022-11-14	ACRVAcrivon Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+35.2K sh	—	—	35,235
2022-03-29	KPTIKaryopharm Therapeutics Inc.A Award	Chief Scientific Officer	AAward	+60K sh	—	—	958,131
2022-03-29	KPTIKaryopharm Therapeutics Inc. · Stock Option (right to buy)A Award	Chief Scientific Officer	AAward	+90K sh	—	—	90,000
2022-02-28	KPTIKaryopharm Therapeutics Inc.S Sale	Chief Scientific Officer	SSale	−6,226 sh	$10.24	−$63.7K	898,131
2022-02-28	KPTIKaryopharm Therapeutics Inc.A Award	Chief Scientific Officer	AAward	+21K sh	—	—	719,983
2022-02-28	KPTIKaryopharm Therapeutics Inc.S Sale	Chief Scientific Officer	SSale	−6,226 sh	$10.24	−$63.7K	713,757
2022-02-28	KPTIKaryopharm Therapeutics Inc. · Stock Option (right to buy)A Award	Chief Scientific Officer	AAward	+27K sh	—	—	27,000
2022-02-17	KPTIKaryopharm Therapeutics Inc.S Sale	Chief Scientific Officer	SSale	−9,088 sh	$12.12	−$110K	904,357
2022-02-17	KPTIKaryopharm Therapeutics Inc.S Sale	Chief Scientific Officer	SSale	−9,079 sh	$12.12	−$110K	698,983
2022-02-07	KPTIKaryopharm Therapeutics Inc.S Sale	Chief Scientific Officer	SSale	−6,707 sh	$9.86	−$66.1K	913,445
2022-02-07	KPTIKaryopharm Therapeutics Inc.S Sale	Chief Scientific Officer	SSale	−6,764 sh	$9.86	−$66.7K	708,062
2021-03-18	KPTIKaryopharm Therapeutics Inc.S Sale	Chief Scientific Officer	SSale	−4,000 sh	$12.39	−$49.6K	714,826
2021-02-25	KPTIKaryopharm Therapeutics Inc.A Award	Chief Scientific Officer	AAward	+57.2K sh	—	—	920,152
2021-02-25	KPTIKaryopharm Therapeutics Inc.A Award	Chief Scientific Officer	AAward	+57.2K sh	—	—	718,826
2021-02-25	KPTIKaryopharm Therapeutics Inc. · Stock Option (right to buy)A Award	Chief Scientific Officer	AAward	+154K sh	—	—	153,500
2021-02-25	KPTIKaryopharm Therapeutics Inc. · Stock Option (right to buy)A Award	Chief Scientific Officer	AAward	+154K sh	—	—	153,500
2021-02-18	KPTIKaryopharm Therapeutics Inc.S Sale	Chief Scientific Officer	SSale	−9,495 sh	$14.83	−$141K	776,452
2021-02-18	KPTIKaryopharm Therapeutics Inc.S Sale	Chief Scientific Officer	SSale	−9,495 sh	$14.83	−$141K	575,126
2021-02-15	KPTIKaryopharm Therapeutics Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+21.8K sh	—	—	785,947
2021-02-15	KPTIKaryopharm Therapeutics Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+21.8K sh	—	—	584,621
2021-02-15	KPTIKaryopharm Therapeutics Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−21.8K sh	—	—	43,600
2021-02-15	KPTIKaryopharm Therapeutics Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−21.8K sh	—	—	43,600
2021-02-11	KPTIKaryopharm Therapeutics Inc.S Sale	Chief Scientific Officer	SSale	−6,642 sh	$15.52	−$103K	764,147
2021-02-11	KPTIKaryopharm Therapeutics Inc.S Sale	Chief Scientific Officer	SSale	−6,601 sh	$15.52	−$102K	562,821
2021-02-05	KPTIKaryopharm Therapeutics Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+14.3K sh	—	—	770,789
2021-02-05	KPTIKaryopharm Therapeutics Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+14.3K sh	—	—	569,422
2021-02-05	KPTIKaryopharm Therapeutics Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−14.3K sh	—	—	42,900
2021-02-05	KPTIKaryopharm Therapeutics Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−14.3K sh	—	—	42,900
2020-10-12	KPTIKaryopharm Therapeutics Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+1,424 sh	$0.03	+$46.992	757,913
2020-10-12	KPTIKaryopharm Therapeutics Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+6,076 sh	$0.03	+$200.508	763,989
2020-10-12	KPTIKaryopharm Therapeutics Inc.S Sale	Chief Scientific Officer	SSale	−7,500 sh	$14.89	−$112K	756,489
2020-10-12	KPTIKaryopharm Therapeutics Inc. · Stock Option (right to buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−1,424 sh	—	—	0
2020-10-12	KPTIKaryopharm Therapeutics Inc. · Stock Option (right to buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−6,076 sh	—	—	0
2020-08-17	KPTIKaryopharm Therapeutics Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+1,477 sh	$0.03	+$48.741	757,966
2020-08-17	KPTIKaryopharm Therapeutics Inc.S Sale	Chief Scientific Officer	SSale	−1,477 sh	$15.00	−$22.2K	756,489
2020-08-17	KPTIKaryopharm Therapeutics Inc. · Stock Option (right to buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−1,477 sh	—	—	6,076
2020-07-15	KPTIKaryopharm Therapeutics Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+7,500 sh	$0.03	+$247.5	763,989
2020-07-15	KPTIKaryopharm Therapeutics Inc.S Sale	Chief Scientific Officer	SSale	−7,500 sh	$19.43	−$146K	756,489
2020-07-15	KPTIKaryopharm Therapeutics Inc. · Stock Option (right to buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−7,500 sh	—	—	1,424
2020-07-10	KPTIKaryopharm Therapeutics Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+7,500 sh	$4.75	+$35.6K	562,622
2020-07-10	KPTIKaryopharm Therapeutics Inc.S Sale	Chief Scientific Officer	SSale	−7,200 sh	$18.98	−$137K	555,422
2020-07-10	KPTIKaryopharm Therapeutics Inc.S Sale	Chief Scientific Officer	SSale	−300 sh	$19.71	−$5,912.01	555,122
2020-07-10	KPTIKaryopharm Therapeutics Inc. · Stock Option (right to buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−7,500 sh	—	—	333,561
2020-07-09	KPTIKaryopharm Therapeutics Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+7,500 sh	$4.75	+$35.6K	763,989
2020-07-09	KPTIKaryopharm Therapeutics Inc.S Sale	Chief Scientific Officer	SSale	−7,500 sh	$19.53	−$146K	756,489
2020-07-09	KPTIKaryopharm Therapeutics Inc. · Stock Option (right to buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−7,500 sh	—	—	377,803

Recent filings

Accepted (ET)
Jun 224
Shacham Sharon0000905148-26-003041
SEC(opens sec.gov)
May 204
Shacham Sharon0000905148-26-002562
SEC(opens sec.gov)
Jun 174
Shacham Sharon0000905148-25-002173
SEC(opens sec.gov)
Jun 244
Shacham Sharon0000905148-24-001776
SEC(opens sec.gov)
Nov 164
Shacham Sharon0001209191-22-057405
SEC(opens sec.gov)
Mar 314
Shacham Sharon0001209191-22-021755
SEC(opens sec.gov)
Mar 24
Shacham Sharon0001209191-22-014626
SEC(opens sec.gov)
Feb 224
Shacham Sharon0001209191-22-011639
SEC(opens sec.gov)
Feb 94
Shacham Sharon0001209191-22-008119
SEC(opens sec.gov)
Mar 234
Shacham Sharon0001209191-21-022487
SEC(opens sec.gov)
Mar 14
Shacham Sharon0001209191-21-015482
SEC(opens sec.gov)

Companies

Address

C/O ACRIVON THERAPEUTICS, INC. 480 ARSENAL WAY, SUITE 100

WATERTOWN, MA, 02472